# US 9,518,107 B2 · Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,518,107 B2 - Document ID: US9518107B2 - Status: Granted - Kind: B2 - Application number: 14/628,644 - Filed: 2015-02-23 - Published: 2015-08-27 - Granted: 2016-12-13 - Earliest claimed: 2010-08-31 - Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem - Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. - Inventors: Uri Wormser - Web page: https://patentgrep.com/patent/US9518107B2 ## CPC - C07K 14/8125: {Alpha-1-antitrypsin} - A61K 38/55: Protease inhibitors - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Isolated polypeptides comprising the amino acid sequence of residues 378-413 of Mus musculus α-1-antitrypsyn (serpin A1c),active fragments thereof, and pharmaceutical compositions comprising same are described. The compositions are useful for treating burns, inflammatory, autoimmune and degenerative diseases. ## Claims ### Claim 1 A method for treating inflammation in a subject in need thereof, said method comprising administering to a subject suffering from a disease selected from the group consisting of an autoimmune disease, a degenerative neurological disease, a degenerative muscle disease, graft rejection, graft versus host disease, allergy, a musculo-skeletal inflammation and sepsis a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide of up to 50 amino acid comprising a sequence sharing at least 95% identity with the sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, and said isolated polypeptide diminishes or abrogates an inflammatory response in the subject. ### Claim 2 (depends on 1) The method according to claim 1, wherein said subject suffers from systemic lupus erythematosus (SLE), multiple sclerosis, arthritis, asthma, inflammatory bowel disease, Crohn's disease, or psoriasis. ### Claim 3 (depends on 2) The method according to claim 2, wherein said subject suffers from systemic lupus erythematosus (SLE). ### Claim 4 (depends on 2) The method according to claim 2, wherein said subject suffers from multiple sclerosis. ### Claim 5 (depends on 2) The method according to claim 2, wherein said subject suffers from psoriasis. ### Claim 6 (depends on 1) The method according to claim 1, wherein said subject suffers from Parkinson's disease, amyotrophic lateral sclerosis, or Alzheimer's disease. ### Claim 7 (depends on 1) The method according to claim 1 wherein said subject suffers from sepsis. ### Claim 8 A method for treating inflammation in a subject in need thereof, said method comprising administering to a subject suffering from a disease selected from the group consisting of an autoimmune disease, a degenerative neurological disease, a degenerative muscle disease, graft rejection, graft versus host disease, allergy, a musculo-skeletal inflammation and sepsis a therapeutically effective amount of an isolated polypeptide of up to 50 amino acids comprising a sequence sharing at least 95% identity with the sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. ### Claim 9 (depends on 8) The method according to claim 8, wherein said subject suffers from systemic lupus erythematosus (SLE), multiple sclerosis, arthritis, asthma, inflammatory bowel disease, Crohn's disease, or psoriasis. ### Claim 10 (depends on 9) The method according to claim 9, wherein said subject suffers from systemic lupus erythematosus (SLE). ### Claim 11 (depends on 9) The method according to claim 9, wherein said subject suffers from multiple sclerosis. ### Claim 12 (depends on 9) The method according to claim 9, wherein said subject suffers from psoriasis. ### Claim 13 (depends on 8) The method according to claim 8, wherein said subject suffers from Parkinson's disease, amyotrophic lateral sclerosis, or Alzheimer's disease. ### Claim 14 (depends on 8) The method according to claim 8, wherein said subject suffers from sepsis. ### Claim 15 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 97% identity with the sequence set forth in SEQ ID NO: 1. ### Claim 16 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 99% identity with the sequence set forth in SEQ ID NO: 1. ### Claim 17 (depends on 8) The method of claim 8, wherein said isolated polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 1. ### Claim 18 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 97% identity with the sequence set forth in SEQ ID NO: 2. ### Claim 19 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 99% identity with the sequence set forth in SEQ ID NO: 2. ### Claim 20 (depends on 8) The method of claim 8, wherein said isolated polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 2. ### Claim 21 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 97% identity with the sequence set forth in SEQ ID NO: 3 or 4. ### Claim 22 (depends on 8) The method of claim 8, wherein said isolated polypeptide has a sequence sharing at least 99% identity with the sequence set forth in SEQ ID NO: 3 or 4. ### Claim 23 (depends on 8) The method of claim 8, wherein said isolated polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 3 or 4.